Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INSY

INSYS Therapeutics (INSY) Stock Price, News & Analysis

INSYS Therapeutics logo

About INSYS Therapeutics Stock (NASDAQ:INSY)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.23
$65,799,000.00
52-Week Range
N/A
Volume
N/A
Average Volume
9.52 million shs
Market Capitalization
$21.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INSY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INSY Stock News Headlines

Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Aldeyra Therapeutics, Inc. (ALDX)
See More Headlines

INSY Stock Analysis - Frequently Asked Questions

INSYS Therapeutics, Inc. (NASDAQ:INSY) issued its quarterly earnings data on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.33. The business's revenue for the quarter was down 68.1% compared to the same quarter last year.

INSYS Therapeutics's stock split before market open on Monday, March 31st 2014.The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were distributed to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
5/10/2019
Today
7/04/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSY
Previous Symbol
NASDAQ:NEOL
Fax
N/A
Employees
226
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.51 million
Net Margins
-346.61%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$82.08 million
Price / Cash Flow
N/A
Book Value
($0.58) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$21.71 million
Optionable
Optionable
Beta
3.21
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:INSY) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners